Webinars

Spatial proteomics: a journey to adopt highly multiplexed immunohistochemistry technologies

Resource: Spatial proteomics: a journey to adopt highly multiplexed immunohistochemistry technologies
About:

Multiplex protein expression analysis in tissue using immunohistochemistry has rapidly evolved over the last decade from 2- and 3-plex assays to a field of new technologies enabling highly multiplexed assays of 40 or more targets. Knowing which of these spatial proteomic technologies would be most effective in your lab or group is not simple. In this presentation we will walk through the value proposition for spatial proteomics, focusing on antibody- and immunohistochemistry-based spatial proteomics platforms, as well as review technical vignettes describing our lab’s experience evaluating and selecting the most appropriate platforms for our lab. We hope that our experience can empower you on your own journey into spatial proteomics.

Agenda:
  • Understanding of spatial proteomics platforms currently available.
  • Pros and cons of a select set of spatial proteomics platforms.
  • Decision criteria for selecting spatial proteomics platforms based on use case and workflow.
Speaker:

Dr. Alexander Klimowicz – Senior Principal Scientist, Boehringer Ingelheim Pharmaceuticals, USA

Alex Klimowicz is a Senior Principal Scientist in the Department of Immunology and Respiratory Discovery Research at Boehringer Ingelheim Pharmaceuticals, Inc. In this capacity he leads the Molecular Histopathology Group, implementing and applying cutting edge in situ techniques, whole slide imaging, and digital image analysis, to deliver translational human disease data to support drug programs and define human patient segments to enable precision medicine. Alex holds a PhD in Molecular Biology, and has over 10 years of experience in the fields of digital pathology and quantitative immunohistochemistry. Prior to moving to Boehringer Ingelheim, Alex was an Adjunct Research Assistant Professor in the Department of Oncology at the University of Calgary, where he led a core quantitative immunohistochemistry lab focused on cancer biomarker research.